Mesna ameliorates intestinal mucosa damage after ifosfamide administration in the rabbit at a dose-related manner

Journal of Surgical Research

Volumn 121, Issue 1, 2004, Pages 84-91

  Ypsilantis, Petros ^a,c   Tentes, Ioannis ^a   Assimakopoulos, Stelios F ^b   Kortsaris, Alexandros ^a   Scopa, Chrisoula D ^b   Simopoulos, Constantinos ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c Medical School   (Greece)

Author keywords

ifosfamide; mesna; mucositis; rabbit

Indexed keywords

ANTIMITOTIC AGENT; DNA FRAGMENT; IFOSFAMIDE; MESNA;

AGAR GEL ELECTROPHORESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATROPHY; CELL PROLIFERATION; CONTROLLED STUDY; CRYPT CELL; DNA DAMAGE; DOSE RESPONSE; DRUG EFFECT; HISTOPATHOLOGY; INTESTINE CRYPT; INTESTINE INJURY; INTESTINE MUCOSA; INTESTINE VILLUS; MITOSIS; MORPHOMETRICS; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RABBIT; RANDOMIZATION;

ANIMALS; APOPTOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; IFOSFAMIDE; INTESTINAL MUCOSA; MESNA; RABBITS;

EID: 4143132484     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jss.2004.03.003     Document Type: Article

References (47)

1. Bell K.A., Perna A.G., Hsu S. Mucositis as a treatment-limiting side effect in the use of capecitabine for the treatment of metastatic breast cancer. J. Am. Acad. Dermatol. 45:2001;790
2. Duncan M., Grant G. Oral and intestinal mucositis - Causes and possible treatments. Aliment. Pharmacol. Ther. 18:2003;853
3. Ikuno N., Soda H., Watanabe M., Oka M. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J. Natl. Cancer Inst. 87:1995;1876
4. Keefe D.M., Brealey J., Goland G.J., Cummins A.G. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut. 47:2000;632
5. Pritchard D.M., Potten C.S., Hickman J.A. The relationships between p53-dependent apoptosis, inhibition of proliferation, and 5-fluorouracil-induced histopathology in murine intestinal epithelia. Cancer Res. 58:1998;5453
6. Booth D., Potten C.S. Protection against mucosal injury by growth factors and cytokines. J. Natl. Cancer Inst. Monogr. 29:2001;16
7. Gibson R.J., Keefe D.M., Clarke J.M., Regester G.O., Thompson F.M., Goland G.J., Edwards B.G., Cummins A.G. The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother. Pharmacol. 50:2002;53
8. Hirano M., Iwakiri R., Fujimoto K., Sakata H., Ohyama T., Sakai T., Joh T., Itoh M. Epidermal growth factor enhances repair of rat intestinal mucosa damaged by oral administration of methotrexate. J. Gastroenterol. 30:1995;169
9. Potten C.S., Booth D., Haley J.D. Pretreatment with transforming growth factor beta-3 protects small intestinal stem cells against radiation damage in vivo. Br. J. Cancer. 75:1997;1454
10. Tavakkolizadeh A., Shen R., Abraham P., Kormi N., Seifert P., Edelman E.R., Jacobs D.O., Zinner M.J., Ashley S.W., Whang E.E. Glucagon-like peptide 2 A new treatment for chemotherapy-induced enteritis. J. Surg. Res. 91:2000;77
11. Cao S., Troutt A.B., Rustum Y.M. Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. Cancer Res. 58:1998;1695
12. Gibson R.J., Keefe D.M., Thompson F.M., Clark J.M., Goland G.J., Cummins A.G. Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig. Dis. Sci. 47:2002;2751
13. Orazi A., Du X., Yang Z., Kashai M., Williams D.A. Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation. Lab. Invest. 75:1996;33
14. Dechant K.L., Brogden R.N., Pilkington T., Faulds D. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs. 42:1991;428
15. Siu L.L., Moore M.J. Use of mesna to prevent ifosfamide-induced urotoxicity. Support. Care Cancer. 6:1998;144
16. Ypsilantis P., Tentes I., Assimakopoulos S.F., Kortsaris A., Scopa C.D., Pitiakoudis M., Simopoulos C. Dose related effects of ifosfamide on enterocyte apoptosis in different sites of the rabbit intestine. Toxicology. 2004;. in press
17. Brade W.P., Herdrich K., Varini M. Ifosfamide-pharmacology, safety and therapeutic potential. Cancer Treat. Rev. 12:1985;1
18. Burton K. A study of the conditions and mechanism of the diphenylamin reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem. J. 62:1956;315
19. Ijiri K., Potten C.S. Response of intestinal cells of differing topographical and hierarchical status to ten cytotoxic drugs and five sources of radiation. Br. J. Cancer. 47:1983;175
20. Ijiri K., Potten C.S. Further studies on the response of intestinal crypt cells of different hierarchical status to eighteen different cytotoxic agents. Br. J. Cancer. 55:1987;113
21. Mesner P.W. Jr, Kaufmann S.H. Methods utilized in the study of apoptosis. Kaufmann S.H. Apoptosis Pharmacological Implications and Therapeutic Opportunities. 1997;57-88 Academic Press, London
22. Filicko J., Lazarus H.M., Flomenberg N. Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation new approaches to prophylaxis and treatment. Bone Marrow Transplant. 31:2003;1
23. Haselberger M.B., Schwinghammer T.L. Efficacy of mesna for prevention of hemorrhagic cystitis after high-dose cyclophosphamide therapy. Ann. Pharmacother. 29:1995;918
24. Furlanut M., Franceschi L. Pharmacology of ifosfamide. Oncology. 65:(Suppl. 2):2003;2
25. Crook T., Souhami R., Whymann G., McLean A. Glutathione depletion as a determinant of sensitivity of human leukemia cells to cyclophosphamide. Cancer Res. 46:1986;5053
26. Lind M.J., McGown A.T., Hadfield J.A., Thatcher N., Crowther D., Fox B.W. The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochem. Pharmacol. 36:1989;1835
27. Chen G., Waxman D.J. Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells. Biochem. Pharmacol. 47:1994;1079
28. Meijer C., Mulder N.H., Timmer-Bosscha H., Wluiter W.J., Meersma G.J., de Vries E.G.E. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res. 52:1992;6885
29. Meister A. Glutathione deficiency produced by inhibition of its synthesis, and its reversal; Applications in research and therapy. Pharmacol. Ther. 51:1991;155
30. Ozols R.F., Louie K.G., Plowman J., Behrens B.C., Fine R.L., Dykes D., Hamilton T.C. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem. Pharmacol. 36:1987;147
31. Benard O., Madesh M., Anup R., Balasubramanian K.A. Apoptotic process in the monkey small intestinal epithelium: I. Association with glutathione level and its efflux. Free Radic. Biol. Med. 26:1999;245
32. Papaconstantinou H.T., Hwang K.O., Rajaraman S., Hellmich M.R., Townsend C.M. Jr, Ko T.C. Glutamine deprivation induces apoptosis in intestinal epithelial cells. Surgery. 124:1998;152
33. Papaconstantinou H.T., Chung D.H., Zhang W., Ansari N.H., Hellmich M.R., Townsend C.M. Jr, Ko T.C. Prevention of mucosal atrophy Role of glutamine and caspases in apoptosis in intestinal epithelial cells. J. Gastrointest. Surg. 4:2000;416
34. Buttke T.M., Sandstrom P.A. Oxidative stress as a mediator of apoptosis. Immunol. Today. 15:1994;7
35. Simon H.U., Haj-Yehia A., Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis. 5:2000;415
36. Meyn R.E., Murray D. Cell cycle effects of alkylating agents. Pharmacol. Ther. 24:1984;147
37. Zhang Z., Leonard S.S., Huang C., Vallyathan V., Castranova V., Shi X. Role of reactive oxygen species and MAPKs in vanadate-induced G(2)/M phase arrest. Free Radic. Biol. Med. 15:2003;1333
38. Gressier B., Cabanis A., Lebegue S., Brunet C., Dine T., Luyckx M., Cazin M., Cazin J.C. Decrease of hypochlorous acid and hydroxyl radical generated by stimulated human neutrophils Comparison in vitro of some thiol-containing drugs. Methods Find. Exp. Clin. Pharmacol. 16:1994;9
39. Shusterman T., Sela S., Cohen H., Kristal B., Sbeit W., Reshef R. Effect of the antioxidant Mesna (2-mercaptoethane sulfonate) on experimental colitis. Dig. Dis. Sci. 48:2003;1177
40. Ormstad K., Orrenius S., Lastbom T., Uehara N., Pohl J., Satekar J., Brock N. Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat. Cancer Res. 43:1983;333
41. Manz I., Dietrich I., Przybylski M., Niemeyer U., Pohl J., Hilgard P., Brock N. Identification and quantification of metabolite conjugates of activated cyclophosphamide and ifosfamide with mesna in urine by ion-pair extraction and fast atom bombardment mass spectrometry. Biomed. Mass Spectrom. 12:1985;545
42. Allan S.G., Smyth J.F., Hay F.G., Leonard R.C., Wolf C.R. Protective effect of sodium-2-mercaptoethanesulfonate on the gastrointestinal toxicity and lethality of cis-diamminedichloroplatinum. Cancer Res. 46:1986;3569
43. Hausheer F.H., Kanter P., Cao S., Haridas K., Seetharamulu P., Reddy D., Petluru P., Zhao M., Murali D., Saxe J.D., Yao S., Martinez N., Zukowski A., Rustum Y.M. Modulation of platinum-induced toxicities and therapeutic index mechanistic insights and first- and second-generation protecting agents. Semin. Oncol. 25:1998;584
44. Brock N., Pohl J., Stekar J., Scheef W. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention - III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna). Eur. J. Cancer Clin. Oncol. 18:1982;1377
45. Gurtoo H.L., Marinello A.J., Berrigan M.J., Bansal S.K., Paul B., Pavelic Z.P., Struck R.F. Effect of thiols on toxicity and carcinostatic activity of cyclophosphamide. Semin. Oncol. 10:(1 Suppl. 1):1983;35
46. Jager A.H., Bogdahn U., Apfel R., Pfeufer B., Dekant A. In vitro studies on interaction of 4-hydroperoxyifosfamide and 2-mercaptoethanesulphonate in malignant gliomas. J. Cancer Res. Clin. Oncol. 119:1993;721
47. Blomgren H., Hallstrom M., Hillgren H. Antitumor activity of 2-mercaptoethanesulfonate (mesna) in vitro. Methods Find. Exp. Clin. Pharmacol. 12:1990;691